Tech and Biotech: Madison Vaccines adds muscle to its fight against prostate cancer; bb7 boasts a honey of a brew

MVI-816 is aimed at men who have been treated for prostate cancer and show a high risk that it will spread. The trial is underway at UW-Madison; now, The Johns Hopkins University and the University of California-San Francisco will participate, too.